Neuregulin stimulation of cardiomyocyte regeneration in mice and human myocardium reveals a therapeutic window.

ABSTRACT: Therapies developed for adult patients with heart failure have been shown to be ineffective in pediatric clinical trials, leading to the recognition that new pediatric-specific therapies for heart failure must be developed. Administration of the recombinant growth factor neuregulin-1 (rNRG1) stimulates regeneration of heart muscle cells (cardiomyocytes) in adult mice. Because proliferation-competent cardiomyocytes are more abundant in growing mammals, we hypothesized that administration of rNRG1 during the neonatal period might be more effective than in adulthood. If so, neonatal rNRG1 delivery could be a new therapeutic strategy for treating heart failure in pediatric patients. To evaluate the effectiveness of rNRG1 administration in cardiac regeneration, newborn mice were subjected to cr

SUBMITTER: Polizzotti BD 

PROVIDER: S-EPMC5360874 | biostudies-literature | 2015 Apr

REPOSITORIES: biostudies-literature